---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-070743"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T11:51:11.696353+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kintara Therapeutics receives Nasdaq bid price noncompliance notice; also equity deficiency

## Summary
- Received Nasdaq notice on Dec 13, 2023 for failing to maintain $1.00 minimum bid price for 30 consecutive days.
- Has 180 days (until June 10, 2024) to regain compliance by closing at $1.00+ for 10 consecutive days.
- Also not compliant with Nasdaq's $2.5M minimum stockholders' equity requirement.
- If compliance not regained, common stock may be delisted to OTC markets, reducing liquidity.
- Considering options including a reverse stock split to cure bid price deficiency.

## SEC filing metadata
- accession: 0000950170-23-070743
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017023070743/0000950170-23-070743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017023070743/ktra-20231213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-070743
- JSON: https://secwatch.observer/filing/0000950170-23-070743.json
- Plain text: https://secwatch.observer/filing/0000950170-23-070743.txt

## Key facts
- Listing & Compliance Notices
  TuHURA Biosciences, Inc./NV received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: December 13, 2023, Kintara Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pri
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017023070743/0000950170-23-070743-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.